

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States, Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/483,434	01/14/2000	JEFFERY L. MILLER	14014.0360	8390
36339	7590 10/01/2003			
NATIONAL INSTITUTE OF HEALTH C/O NEEDLE & ROSENBERG, P.C. SUITE 1000 999 PEACHTREE STREET ATLANTA, GA 30303			EXAMINER	
			LEFFERS JR, GERALD G	
			ART UNIT	PAPER NUMBER
ATLANTA,	, GA 30303		1636 TO 10/01/2005	26
			DATE MAILED: 10/01/2003	,

Please find below and/or attached an Office communication concerning this application or proceeding.

	-	Application No.	Applicant(s)			
`		09/483,434	MILLER ET AL.			
	Office Action Summary	Examiner	Art Unit			
		Gerald G Leffers Jr., PhD	1636			
	The MAILING DATE of this communication a	ppears on the cover sheet with the	correspondence address			
Peri d fo	r Reply					
THE I - External after - If the - If NO - Failur - Any rearres	ORTENED STATUTORY PERIOD FOR REP MAILING DATE OF THIS COMMUNICATION nsions of time may be available under the provisions of 37 CFR 1 SIX (6) MONTHS from the mailing date of this communication. In period for reply specified above is less than thirty (30) days, a repriod for reply is specified above, the maximum statutory perior reto reply within the set or extended period for reply will, by staturely received by the Office later than three months after the mailed patent term adjustment. See 37 CFR 1.704(b).		timely filed lays will be considered timely. from the mailing date of this communication. NED (35 U.S.C. § 133).			
Status 1)⊠	Responsive to communication(s) filed on 25	5 July 2003 .				
2a)⊠		This action is non-final.				
3)□	Oises this application is in condition for allow	wance except for formal matters,	prosecution as to the merits is			
·	closed in accordance with the practice under ion of Claims	er <i>Ex parte Quayle</i> , 1935 C.D. 11	, 453 O.G. 213.			
	Claim(s) <u>3,7,9,10 and 18</u> is/are pending in t	he application.				
٠,١	4a) Of the above claim(s) is/are withd	rawn from consideration.				
5)⊠	Claim(s) 3,9 and 10 is/are allowed.					
-	Claim(s) <u>7 and 18</u> is/are rejected.					
	Claim(s) is/are objected to.					
8)□	Claim(s) are subject to restriction and	i/or election requirement.				
	tion Papers					
9) 🗌	The specification is objected to by the Exami	ner.	vaminer			
10)	The drawing(s) filed on is/are: a) ac	cepted or b) objected to by the L	See 37 CFR 1.85(a).			
	Applicant may not request that any objection to The proposed drawing correction filed on	is: a) approved b) disap	proved by the Examiner.			
11)	If approved, corrected drawings are required in	reply to this Office action.	,			
120□	The oath or declaration is objected to by the					
			•			
Priority	under 35 U.S.C. §§ 119 and 120 Acknowledgment is made of a claim for fore	eian priority under 35 U.S.C. § 11	9(a)-(d) or (f).			
) All b) Some * c) None of:					
l a	1.☐ Certified copies of the priority docum	ents have been received.				
	2. Certified copies of the priority documents have been received in Application No					
	Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).					
*	See the attached detailed Office action for a	list of the certified copies not reci	eived.			
14)⊠	Acknowledgment is made of a claim for dome	estic priority under 35 U.S.C. § 1	19(e) (to a provisional application).			
	 a) The translation of the foreign language Acknowledgment is made of a claim for dom 	provisional application has been	received.			
Attachme		•				
2) \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	tice of References Cited (PTO-892) tice of Draftsperson's Patent Drawing Review (PTO-948) ormation Disclosure Statement(s) (PTO-1449) Paper No(5) Notice of Infor	mary (PTO-413) Paper No(s) mal Patent Application (PTO-152)			
			- 1 (D - 1) 07			

Application/Control Number: 09/483,434

Art Unit: 1636

DETAILED ACTION

Receipt is acknowledged of an amendment, filed 7/31/03 as Paper No. 24, in which claims were amended (claims 7, 9 and 18) and in which claim 17 was cancelled. Claims 3, 7, 9-10 and 18 are pending in the instant application.

Any rejection of record in the previous action not addressed herein is withdrawn. The new grounds of rejection made herein were necessitated by applicants' amendment of the claims in Paper No. 24. Therefore, this action is FINAL.

Oath/Declaration

Receipt is acknowledged of a substitute Declaration filed as Part of Paper No. 24, which has been properly executed by all of the inventors. The outstanding objection to the Declaration has been obviated and is withdrawn.

Claim Rejections - 35 USC § 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 7 and 18 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

Application/Control Number: 09/483,434

Art Unit: 1636

Both of the claims have been amended to read "... and wherein the method is not therapeutic." The support for the amendment from the instant specification (i.e. page 9, lines 4-7) cited in the response of Paper No. 24 does not, in fact, provide support for such a negative limitation. The passage cited in the response merely indicates that the methods of the invention can be used for diagnosis, prophylactic and/or therapeutic treatment. There is no literal support for excluding methods of delivery of nucleic acids to a cell *in vivo* wherein there is no intended therapeutic benefit. For example, there is no description in the originally filed specification of a method of delivering a nucleic acid to a cell *in vivo* in order to diagnose a disease or condition. Therefore, the added limitation is impermissible NEW MATTER.

Relevant Art

The following reference appears to be relevant art for examination of the pending claims, but the examiner has not been able to obtain a copy of the reference. As the authors of this work appear to be two of the inventors of the instant specification, it is requested that applicants provide a copy of the reference. The reference is as follows:

Wojda, U., Miller, J. L. "Endocytosis mediated by biotin-avidin crosslinking of surface proteins does not require GPI-proteins" Molecular Biology of the Cell (November 1997), Vol. 8, No. SUPPL., page 86A.

Conclusion

Claims 3, 9-10 are allowed. Claims 7 and 18 are rejected.

Page 4

Application/Control Number: 09/483,434

Art Unit: 1636

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Gerald G Leffers Jr., PhD whose telephone number is (703) 308-6232. The examiner can normally be reached on 9:30am-6:00pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Remy Yucel can be reached on (703) 305-1998. The fax phone number for the organization where this application or proceeding is assigned is (703) 872-9306.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0196.

GERRY LEFFERS

DRIMARY EXAMINER

Gerald G Leffers Jr., PhD Examiner Art Unit 1636